Literatuur
- Finn RS et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. The New England journal of medicine. 2020; 382(20): 1894-905
- Llovet JM et al. Sorafenib in advanced hepatocellular carcinoma. The New England journal of medicine. 2008; 359(4): 378-90
- Bruix J et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2017; 389(10064): 56-66
Commissie BOM adviezen
Ga naar de commissie BOM adviezen over hepatocellulair carcinoom.
Richtlijnen
Ga naar de richtlijn Hepatocellulair carcinoom in de FMS richtlijnendatabase.